Bacterial Metabolism Affects the C. elegans Response to Cancer Chemotherapeutics

Cell

Volumn 169, Issue 3, 2017, Pages 431-441.e8

  García González, Aurian P ^a   Ritter, Ashlyn D ^a   Shrestha, Shaleen ^a   Andersen, Erik C ^b   Yilmaz, L Safak ^a   Walhout, Albertha J M ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

5 FU; C. elegans, bacteria; camptothecin; cancer; chemotherapeutics; drug efficacy; FUDR; microbiota; nucleotide metabolism

Indexed keywords

CAMPTOTHECIN; FLOXURIDINE; FLUOROURACIL; 5-FLUORO-2'-DEOXYURIDINE; ANTINEOPLASTIC AGENT; DEOXYURIDINE; PYRIMIDINE NUCLEOSIDE;

ARTICLE; BACTERIAL GENE; BACTERIAL METABOLISM; CAENORHABDITIS ELEGANS; CANCER CHEMOTHERAPY; COMAMONAS; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DNA METABOLISM; DRUG EFFICACY; ESCHERICHIA COLI; GENETIC SCREENING; IMMUNE RESPONSE; NONHUMAN; NUCLEOTIDE METABOLISM; PRIORITY JOURNAL; RNA METABOLISM; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; ANIMAL; ANIMAL MODEL; COLORECTAL NEOPLASMS; DIET; GENETICS; HUMAN; INTESTINE FLORA; METABOLISM; MICROBIOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; CAENORHABDITIS ELEGANS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; COMAMONAS; DEOXYURIDINE; DIET; ESCHERICHIA COLI; FLUOROURACIL; GASTROINTESTINAL MICROBIOME; HUMANS; MODELS, ANIMAL; PYRIMIDINE NUCLEOSIDES;

EID: 85018525562     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2017.03.046     Document Type: Article

References (30)

1. Andrews, J.M., The development of the BSAC standardized method of disc diffusion testing. J. Antimicrob. Chemother. 48:Suppl 1 (2001), 29–42.
2. Baba, T., Ara, T., Hasegawa, M., Takai, Y., Okumura, Y., Baba, M., Datsenko, K.A., Tomita, M., Wanner, B.L., Mori, H., Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection. Mol. Syst. Biol., 2, 2006, 2006.0008.
3. Berg, M., Stenuit, B., Ho, J., Wang, A., Parke, C., Knight, M., Alvarez-Cohen, L., Shapira, M., Assembly of the Caenorhabditis elegans gut microbiota from diverse soil microbial environments. ISME J. 10 (2016), 1998–2009.
4. Boettcher, B., Meister, A., Conversion of UMP, an allosteric inhibitor of carbamyl phosphate synthetase, to an activator by modification of the UMP ribose moiety. J. Biol. Chem. 256 (1981), 5977–5980.
5. Braxton, B.L., Mullins, L.S., Raushel, F.M., Reinhart, G.D., Allosteric dominance in carbamoyl phosphate synthetase. Biochemistry 38 (1999), 1394–1401.
6. Brennan, C.A., Garrett, W.S., Gut microbiota, inflammation, and colorectal cancer. Annu. Rev. Microbiol. 70 (2016), 395–411.
7. Brenner, S., The genetics of Caenorhabditis elegans. Genetics 77 (1974), 71–94.
8. Cabreiro, F., Au, C., Leung, K.-Y., Vergara-Irigaray, N., Cochemé, H.M., Noori, T., Weinkove, D., Schuster, E., Greene, N.D.E., Gems, D., Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism. Cell 153 (2013), 228–239.
9. Dirksen, P., Marsh, S.A., Braker, I., Heitland, N., Wagner, S., Nakad, R., Mader, S., Petersen, C., Kowallik, V., Rosenstiel, P., et al. The native microbiome of the nematode Caenorhabditis elegans: gateway to a new host-microbiome model. BMC Biol., 14, 2016, 38.
10. Félix, M.A., Braendle, C., The natural history of Caenorhabditis elegans. Curr. Biol. 20 (2010), R965–R969.
11. Félix, M.-A., Duveau, F., Population dynamics and habitat sharing of natural populations of Caenorhabditis elegans and C. briggsae. BMC Biol., 10, 2012, 59.
12. Gusarov, I., Gautier, L., Smolentseva, O., Shamovsky, I., Eremina, S., Mironov, A., Nudler, E., Bacterial nitric oxide extends the lifespan of C. elegans. Cell 152 (2013), 818–830.
13. Ison, G., Beaver, J.A., McGuinn, W.D. Jr., Palmby, T.R., Dinin, J., Charlab, R., Marathe, A., Jin, R., Liu, Q., Chen, X.H., et al. FDA approval: uridine triacetate for the treatment of patients following fluorouracil or capecitabine overdose or exhibiting early-onset severe toxicities following administration of these drugs. Clin. Cancer Res. 22 (2016), 4545–4549.
14. Longley, D.B., Harkin, D.P., Johnston, P.G., 5-fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer 3 (2003), 330–338.
15. MacNeil, L.T., Watson, E., Arda, H.E., Zhu, L.J., Walhout, A.J.M., Diet-induced developmental acceleration independent of TOR and insulin in C. elegans. Cell 153 (2013), 240–252.
16. Orth, J.D., Conrad, T.M., Na, J., Lerman, J.A., Nam, H., Feist, A.M., Palsson, B.O., A comprehensive genome-scale reconstruction of Escherichia coli metabolism–2011. Mol. Syst. Biol., 7, 2011, 535.
17. Pommier, Y., Topoisomerase I inhibitors: camptothecins and beyond. Nat. Rev. Cancer 6 (2006), 789–802.
18. Schiff, M., Benoist, J.F., Tilea, B., Royer, N., Giraudier, S., Ogier de Baulny, H., Isolated remethylation disorders: do our treatments benefit patients?. J. Inherit. Metab. Dis. 34 (2011), 137–145.
19. Scott, T.A., Quintaneiro, L.M., Norvaisas, P., Lui, P.P., Wilson, M.P., Leung, K.-Y., Herrera-Dominguez, L., Sudiwala, S., Pessia, A., Clayton, P.T., et al. Host-microbe co-metabolism dictates cancer drug efficacy in C. elegans. Cell 169 (2017), 442–456 this issue.
20. Sivan, A., Corrales, L., Hubert, N., Williams, J.B., Aquino-Michaels, K., Earley, Z.M., Benyamin, F.W., Lei, Y.M., Jabri, B., Alegre, M.L., et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350 (2015), 1084–1089.
21. Sommer, F., Bäckhed, F., The gut microbiota–masters of host development and physiology. Nat. Rev. Microbiol. 11 (2013), 227–238.
22. Tawornsamretkit, I., Thanasomboon, R., Thaiprasit, J., Waraho, D., Cheevadhanarak, S., Meechai, A., Analysis of metabolic network of synthetic Escherichia coli producing linalool using constraint-based modeling. Procedia Comput. Sci. 11 (2012), 24–35.
23. Vétizou, M., Pitt, J.M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M.P., Duong, C.P., et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350 (2015), 1079–1084.
24. Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., Enot, D.P., Pfirschke, C., Engblom, C., Pittet, M.J., et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 342 (2013), 971–976.
25. Watson, E., Walhout, A.J., Caenorhabditis elegans metabolic gene regulatory networks govern the cellular economy. Trends Endocrinol. Metab. 25 (2014), 502–508.
26. Watson, E., MacNeil, L.T., Arda, H.E., Zhu, L.J., Walhout, A.J.M., Integration of metabolic and gene regulatory networks modulates the C. elegans dietary response. Cell 153 (2013), 253–266.
27. Watson, E., MacNeil, L.T., Ritter, A.D., Yilmaz, L.S., Rosebrock, A.P., Caudy, A.A., Walhout, A.J.M., Interspecies systems biology uncovers metabolites affecting C. elegans gene expression and life history traits. Cell 156 (2014), 759–770.
28. Watson, E., Yilmaz, L.S., Walhout, A.J.M., Understanding metabolic regulation at a systems level: metabolite sensing, mathematical predictions and model organisms. Annu. Rev. Genet. 49 (2015), 553–575.
29. Watson, E., Olin-Sandoval, V., Hoy, M.J., Li, C.-H., Louisse, T., Yao, V., Mori, A., Holdorf, A.D., Troyanskaya, O.G., Ralser, M., Walhout, A.J., Metabolic network rewiring of propionate flux compensates vitamin B12 deficiency in C. elegans. eLife, 5, 2016, e17670.
30. Yilmaz, L.S., Walhout, A.J.M., Worms, bacteria, and micronutrients: an elegant model of our diet. Trends Genet. 30 (2014), 496–503.